Aberrant proteins expressed in skin fibroblasts of Parkinson’s disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes. Sawangareetrakul P, Ngiwsara L, Champattanachai V*, Chokchaichamnankit D, Saharat K, Ketudat Cairns JR, Srisomsap C, Khwanraj K, Dharmasaroja P, Pulkes T, Svasti J. Biomed Rep. 2021 Apr;14(4):36.

01 Apr 2021
0
0

Aberrant proteins expressed in skin fibroblasts of Parkinson’s disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes.

Sawangareetrakul P, Ngiwsara L, Champattanachai V*, Chokchaichamnankit D, Saharat K, Ketudat Cairns JR, Srisomsap C, Khwanraj K, Dharmasaroja P, Pulkes T, Svasti J.

Biomed Rep. 2021 Apr;14(4):36.

Tags

Share this

Related Posts

Gerhauser, C., Klimo, K., Heiss, E., Neumann, I., Gamal-Eldeen, A., Knauft, J., . . . Frank, N. (2003). Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res, 523-524, 163-172. doi:10.1016/s0027-5107(02)00332-9
01 Feb 2003
0

Gerhauser, C., Klimo, K., Heiss, E., Neumann, I., Gamal-Eldeen, A., Knauft, J., . . . Frank, N. (2003). Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res, 523-524, 163-172. doi:10.1016/s0027-5107(02)00332-9

Gerhauser, C., Klimo, K., Heiss, E., Neumann, I., Gamal-Eldeen, A., Knauft, J., . . . Frank, N. (2003). Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res, 523-524, 163-172. doi:10.1016/s0027-5107(02)00332-9
View More

Recent Posts